JNJ-74699157

Phase 1Small molecule

Johnson & Johnson

JNJ-74699157 is one of 10 small molecule programs targeting Neurodegenerative Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurodegenerative DiseaseActive, not recruiting

Neurodegenerative DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Neurodegenerative Disease

#DrugCompanyPhaseTrials

Nuplazid

AACADIA Pharmaceuticals Inc.

Approved

3 2

Robitussin

Aricept

1 4

Namenda

AbbVie

Preclinical

1 5

THK-5351

JJae Seung Kim

Phase 2

1 6

Intropin

Pfizer

Preclinical

—7

MC225

UUniversity Medical Center Groningen

Phase 2

1 8

Citicoline

UUniversity of Texas Southwestern Medical Center

JNJ-74699157

1 10

SNP318

SSciNeuro

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

KRAS G12C Mutation1 trial

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04006301·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JNJ-74699157. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-74699157 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-74699157. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Johnson & Johnson

JNJ-74699157

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

KRAS G12C Mutation1 trial

References

Drug Info

Quick Facts

Related News